VIAN Therapeutics is a visionary virtual pharma startup at the forefront of combating microvascular retinal diseases. Focused on conditions like diabetic retinopathy and age-related macular degeneration, we're pioneering a novel solution: VIAN-c4551, a groundbreaking cyclic peptide drug delivered via convenient eyedrop administration. By swiftly stabilizing retinal blood vessels, our non-invasive approach aims to halt vision deterioration earlier than traditional methods (e.g., intraocular injections). With millions affected, VIAN Therapeutics aims to redefine ocular care, offering hope for clearer sight and a brighter future of retinal health.
Company Details
- Employees
- 5
- Founded
- -
- Address
- San Francisco , Ca, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.viantx.com
- Keywords
- angiogenesis, peptides, vasopermeability, diabetic retinopathy, diabetic macular edema, AMD, macular degeneration, oncology, angiogenesis inhibitors, antiangiogenic, eye drop.
- HQ
- San Francisco , CA
Vian Therapeutics Questions
Vian Therapeutics's website is http://www.viantx.com
Vian Therapeutics's LinkedIn profile is https://www.linkedin.com/company/viantx
Vian Therapeutics has
5 employees.
View email and phone details for 5
employees at Vian Therapeutics.
Vian Therapeutics's industry is
Biotechnology Research
Vian Therapeutics's top competitors are
Stream Genomics,
Acerna Technologies,
Sayenza Biosciences,
Reactosome,
Anviron,
Mediprint Ophthalmics,
Interface Biosciences,
Acrobat Genomics,
Engage Bio,
Novaliq Gmbh.
Vian Therapeutics's categories are Biotechnology Research
Vian Therapeutics's founding year is 2023
